Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lovastatin

FDA-approved product (tablet, oral), marketed as Altoprev, Lovastatin, Mevacor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lovastatin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atherosclerosis
  • Cardiovascular disease
  • Coronary artery disease
  • Coronary atherosclerosis
  • Hypercholesterolemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
FDA pharmacologic class
HMG-CoA Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lovastatin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lovastatin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

    NCT02252328 · start 2015-09

    Registered record
    Registry ID
    NCT02252328
    Conditions
    Uveitis
    Interventions
    Simvastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2015-09
    Completion
    2019-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis
    InterventionSimvastatin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Pharmacological Treatment of Rett Syndrome With Statins

    NCT02563860 · start 2015-07

    Registered record
    Registry ID
    NCT02563860
    Conditions
    Rett Syndrome
    Interventions
    Lovastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-07
    Completion
    2016-07
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRett Syndrome
    InterventionLovastatin
    PhasePhase 2
    Registry statusCompleted

  • Acupuncture and Moxibustion for Hyperlipemia

    NCT02269046 · start 2014-12

    Registered record
    Registry ID
    NCT02269046
    Conditions
    Hyperlipidemias
    Interventions
    acupuncture and moxibustion; Simvastatin; Therapeutic Lifestyle Change
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-12
    Completion
    2017-09
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemias
    Interventionacupuncture and moxibustion; Simvastatin; Therapeutic Lifestyle Change
    PhaseNot applicable
    Registry statusUnknown

  • Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.

    NCT05750602 · start 2013-11

    Registered record
    Registry ID
    NCT05750602
    Conditions
    Hypercholesterolemia
    Interventions
    LIMICOL; PLACEBO
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-11
    Completion
    2018-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionLIMICOL; PLACEBO
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

    NCT01420549 · start 2013-03

    Registered record
    Registry ID
    NCT01420549
    Conditions
    Hypercholesterolemia; Dyslipidemia
    Interventions
    Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-11
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia; Dyslipidemia
    InterventionRosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.; Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
    PhasePhase 3
    Registry statusCompleted

  • Statin Recapture Therapy Before Coronary Artery Bypass Grafting

    NCT01715714 · start 2012-11-07

    Registered record
    Registry ID
    NCT01715714
    Conditions
    Coronary Artery Disease
    Interventions
    Statin Recapture Therapy; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11-07
    Completion
    2020-09-27
    Enrolment
    2,630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionStatin Recapture Therapy; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

    NCT01725230 · start 2012-11

    Registered record
    Registry ID
    NCT01725230
    Conditions
    Rheumatoid Arthritis
    Interventions
    Fostamatinib; Rosuvastatin; Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-11
    Completion
    2013-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionFostamatinib; Rosuvastatin; Simvastatin
    PhasePhase 1
    Registry statusCompleted

  • Single Pill to Avert Cardiovascular Events

    NCT01313702 · start 2012-10

    Registered record
    Registry ID
    NCT01313702
    Conditions
    Cardiovascular Disease
    Interventions
    polipillV1; polipillV2; usual care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-10
    Completion
    2014-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionpolipillV1; polipillV2; usual care
    PhasePhase 3
    Registry statusWithdrawn

  • A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

    NCT01674712 · start 2012-06

    Registered record
    Registry ID
    NCT01674712
    Conditions
    Dyslipidemia
    Interventions
    Fixed Combination of Fenofibrate/simvastatin 145/20 mg; Simvastatin 20 mg; Fenofibrate 145 mg; Fixed Combination of Fenofibrate/simvastatin 145/40 mg; Simvastatin 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2013-10
    Enrolment
    575

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemia
    InterventionFixed Combination of Fenofibrate/simvastatin 145/20 mg; Simvastatin 20 mg; Fenofibrate 145 mg; Fixed Combination of Fenofibrate/simvastatin 145/40 mg +1 more
    PhasePhase 3
    Registry statusCompleted

  • Genetic Influence on Statin Pharmacodynamics

    NCT01569854 · start 2012-03

    Registered record
    Registry ID
    NCT01569854
    Conditions
    Hyperlipidemia; Hypercholesterolemia; Dyslipidemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2012-03
    Completion
    2022-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipidemia; Hypercholesterolemia; Dyslipidemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • A Study To Estimate The Effect Of Repeated Dosing of PF-05175157 On The Pharmacokinetics Of A Single Dose Of Simvastatin In Healthy Adult Subjects

    NCT01469468 · start 2011-11

    Registered record
    Registry ID
    NCT01469468
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Simvastatin; PF-05175157
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2011-12
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionSimvastatin; PF-05175157
    PhasePhase 1
    Registry statusCompleted

  • Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

    NCT01441349 · start 2011-08

    Registered record
    Registry ID
    NCT01441349
    Conditions
    Small Cell Lung Carcinoma
    Interventions
    IP chemotherapy; IP chemotherapy plus simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-08
    Completion
    2022-12-31
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Carcinoma
    InterventionIP chemotherapy; IP chemotherapy plus simvastatin
    PhasePhase 2
    Registry statusUnknown

  • Effect of Cilostazol on the Pharmacokinetics of Simvastatin

    NCT01383395 · start 2011-06

    Registered record
    Registry ID
    NCT01383395
    Conditions
    Healthy
    Interventions
    simvastatin/cilostazol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2011-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionsimvastatin/cilostazol
    PhasePhase 1
    Registry statusCompleted

  • Trial of XELIRI/FOLFIRI + Simvastatin Followed by Simvastatin Maintenance in Metastatic Colorectal Cancer

    NCT01238094 · start 2010-04

    Registered record
    Registry ID
    NCT01238094
    Conditions
    Colorectal Cancer
    Interventions
    Simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-04
    Completion
    2014-05
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionSimvastatin
    PhasePhase 3
    Registry statusUnknown

  • Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

    NCT01096940 · start 2010-03

    Registered record
    Registry ID
    NCT01096940
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    AZD1656; simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-03
    Completion
    2010-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionAZD1656; simvastatin
    PhasePhase 1
    Registry statusCompleted